Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Long-Term Clinical Outcomes After Fetal Cell Transplantation in Parkinson Disease Implications for the Future of Cell Therapy
JAMA 311:617-618, Bega, D. & Krainc, D., 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Extended-Release Pramipexole in Advanced Parkinson Disease
Neurol 77:767-774, Schapira, A.H.V.,et al, 2011
Pallidal Versus Subthalamic Deep-Brain Stimulation for Parkinsons Disease
NEJM 362:2077-2091, Pollett,K.A., et al, 2010
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial
JAMA 301:63-73,104, Weaver,F.M.,et al, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
A Randomized Trial of Deep-Brain Stimulation for Parkinsons Disease
NEJM 355:896-908, Deuschl,G.,et al, 2006
Five-Year Follow-up of Bilateral Stimulatioin of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 349:1925-1934,1888, Krack,P.,et al, 2003
Long-Term Follow-Up of Thalamic Deep Brain Stimulation for Essential and Parkinsonian Tremor
Neurol 61:1601-1604, Kumar,R.,et al, 2003
Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002
Bilateral Subthalamic Nucleus Stimulation Improves Health-Related Quality of Life in PD
Neurol 59:1976-1978, Lagrange,E.,et al, 2002
Deep Brain Stimulation of the Subthalamic Nucleus: Clinical Effectiveness and Safety
Neurol 56:552-554, Lopiano,L.,et al, 2001
Deep Brain Stimulation in the Treatment of Parkinson's Disease,A Cost-Effectiveness Analysis
Neurol 57:663-671, Tomaszewski,K.J.&Holloway,R.G., 2001
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Long-Term Follow-Up of Unilateral Pallidotomy in Advanced Parkinson's Disease
NEJM 342:1708-1714, Fine,J.,et al, 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Arch Neurol 56:179-187, Hauser,R.A.,et al, 1999
Unilateral Pallidotomy for Parkinson's Disease:Results after More Than 1 Year
JNNP 67:511-517, Schrag,A.,et al, 1999
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Effect of Selegiline on Mortality in Patients with Parkinson's Disease
Neurol 51:825-830, Olanow,C.W.,et al, 1998
Surgery for Parkinson's Disease
JNNP 62:2-8, Obeso,J.A.,et al, 1997
Stereotactic Pallidotomy for Parkinson's Disease:A Long-Term Follow-up of Unilateral Pallidotomy
Neurol 48:1273-1277, Fazzini,E.,et al, 1997
Survival & Prolif of Nonneural Tissu, with Obstr of Cereb Ventric, In Parkinson Pt Trt with Fetal Allografts
Neurol 46:1219-1225, Folkerth,R.D.&Durso,R., 1996
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996